MarylandSB 05622026 Regular SessionSenate

State Board of Pharmacy - Prescriber-Pharmacist Agreements - Treatment of Opioid Use Disorders

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

3 provisions identified: 1 benefits, 1 costs, 1 mixed.

Certified midwives can partner with pharmacists

Beginning July 1, 2026, licensed certified midwives count as authorized prescribers in Maryland. They can enter prescriber–pharmacist agreements to manage patient therapy. This can help more patients get pharmacist‑managed care.

Pharmacists must file agreements with Board

Beginning July 1, 2026, pharmacists who sign a prescriber–pharmacist agreement must send a copy to the Maryland Board of Pharmacy. They must also file any later changes to the agreement. This shifts the filing duty from the prescriber to the pharmacist and adds an admin step.

Pharmacists can treat opioid disorder with checks

Beginning July 1, 2026, pharmacists can treat opioid use disorder under a prescriber–pharmacist agreement. The pharmacist must have DEA and state controlled‑substance registrations, complete required training, and follow an approved protocol. Before starting or changing controlled‑substance therapy, the pharmacist must check the state Prescription Drug Monitoring Program. This expands access to OUD treatment with safety steps.

Sponsors & Cosponsors

Sponsor

Dawn Gile
Democratic • Senate

Cosponsors

There are no cosponsors for this bill.

Roll Call Votes

All Roll Calls

Yes: 177 • No: 0

House vote • 4/2/2026

Third Reading Passed

Yes: 132 • No: 0 • Other: 3

Senate vote • 3/12/2026